Agree with your order. It makes little sense from my perspective to approach US investors with essentially the same story we have now. As others have mentioned, waiting for FDA Clearance will likely be perceived as FDA Approval = still a lot of risk.
Better off going to these investors with FDA under the belt, the investment narrative is significantly stronger. With this revenue getting locked in it allows us to kick the raise down the road somewhat. Ideally, until after the .
I could be missing something but I’d be disappointed if we did another raise with no material positive change regarding Conneqt having happened. After thIs revenue is confirmed, FDA clearance and then the CES would be a very strong case to put towards US investment. At a much higher MC and also significantly less dilution.
IMO DYOR
Add to My Watchlist
What is My Watchlist?
